Literature DB >> 1934467

Importance of creatinine analyses of urine when screening for abused drugs.

P Lafolie1, O Beck, G Blennow, L Boréus, S Borg, C E Elwin, L Karlsson, G Odelius, P Hjemdahl.   

Abstract

We report here a simple method involving urine creatine measurements for testing authenticity and reducing false-negative results in urine testing for drugs of abuse. Urinary creatinine in consecutive patient samples (n = 176) ranged between 0.1 and 31.9 mmol/L (mean 9.8 +/- SD 6.2) and the osmolality in these urines ranged between 49 and 1183 mOsm/kg (mean 595 +/- SD 276). With other consecutive samples in which creatinine was (arbitrarily chosen) less than 4.3 mmol/L (n = 85), the correlation with osmolality was lower. In 10 randomly selected urine samples from different patients, all "clean" for all drugs of abuse in initial immunological drug testing with approved methodology (in which creatinine was less than 4.3 mmol/L and osmolality was less than 200 mOsm/kg), five patients turned out to be drug positive after a simple concentration by volume. In a formerly heavy smoker of cannabis, the excretion of cannabinoids and creatinine was monitored for 93 days. The substances showed very good correlation throughout this period (r = 0.93, P less than 0.001), whereas simple measurements of cannabinoid concentrations would have falsely indicated several relapses of cannabis abuse. Urine samples used in drug-abuse testing should be tested for creatinine; if creatinine is less than 4.0 mmol/L, negative results for drugs may not be valid.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1934467

Source DB:  PubMed          Journal:  Clin Chem        ISSN: 0009-9147            Impact factor:   8.327


  16 in total

Review 1.  Human cannabinoid pharmacokinetics.

Authors:  Marilyn A Huestis
Journal:  Chem Biodivers       Date:  2007-08       Impact factor: 2.408

2.  Immunoassays for drug screening in urine : Chances, challenges, and pitfalls.

Authors:  Harald Schütz; Alexandre Paine; Freidoon Erdmann; Günter Weiler; Marcel A Verhoff
Journal:  Forensic Sci Med Pathol       Date:  2006-06       Impact factor: 2.007

3.  Urinary 11-nor-9-carboxy-tetrahydrocannabinol elimination in adolescent and young adult cannabis users during one month of sustained and biochemically-verified abstinence.

Authors:  Randi Melissa Schuster; Kevin Potter; Ryan Vandrey; Maya Hareli; Jodi Gilman; David Schoenfeld; A Eden Evins
Journal:  J Psychopharmacol       Date:  2019-09-19       Impact factor: 4.153

Review 4.  Paper-based assays for urine analysis.

Authors:  Eric Lepowsky; Fariba Ghaderinezhad; Stephanie Knowlton; Savas Tasoglu
Journal:  Biomicrofluidics       Date:  2017-10-17       Impact factor: 2.800

5.  Prolonged cannabis withdrawal in young adults with lifetime psychiatric illness.

Authors:  Randi Melissa Schuster; Madeleine Fontaine; Emily Nip; Haiyue Zhang; Ailish Hanly; A Eden Evins
Journal:  Prev Med       Date:  2017-02-27       Impact factor: 4.018

6.  Interrelationship of CB1R and OBR pathways in regulation of metabolic, neuroendocrine, and behavioral responses to food restriction and voluntary wheel running.

Authors:  Abdoulaye Diane; Donna F Vine; James C Russell; C Donald Heth; W David Pierce; Spencer D Proctor
Journal:  J Appl Physiol (1985)       Date:  2014-06-05

7.  A contingency management method for 30-days abstinence in non-treatment seeking young adult cannabis users.

Authors:  Randi Melissa Schuster; Ailish Hanly; Jodi Gilman; Alan Budney; Ryan Vandrey; A Eden Evins
Journal:  Drug Alcohol Depend       Date:  2016-08-28       Impact factor: 4.492

8.  Differentiating new cannabis use from residual urinary cannabinoid excretion in chronic, daily cannabis users.

Authors:  Eugene W Schwilke; Rod G Gullberg; William D Darwin; C Nora Chiang; Jean Lud Cadet; David A Gorelick; Harrison G Pope; Marilyn A Huestis
Journal:  Addiction       Date:  2010-12-06       Impact factor: 6.526

9.  A rat model to determine the biomedical consequences of concurrent ethanol ingestion and cigarette smoke exposure.

Authors:  Martha J Gentry-Nielsen; Elizabeth Vander Top; Mary U Snitily; Carol A Casey; Laurel C Preheim
Journal:  Alcohol Clin Exp Res       Date:  2004-07       Impact factor: 3.455

10.  Quantification of a methadone metabolite (EDDP) in urine: assessment of compliance.

Authors:  Michael E M Larson; Thomas M Richards
Journal:  Clin Med Res       Date:  2009-11-17
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.